To include your compound in the COVID-19 Resource Center, submit it here.

Xgeva denosumab: Additional Phase III data

Additional data from the double-blind, head-to-head, international Phase III 20050103 trial in 1,901 patients with advanced prostate cancer showed that median time to worsening of pain interference defined as a >=2 point increase in BPI score was non-significantly longer for

Read the full 401 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers